ReviewJournal of clinical medicine2017
Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders.
Review in Journal of clinical medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 88 citations in OpenAlex.
- Vonicog Alfa versus Plasma-Derived von Willebrand Factor during Hospitalization: Results of an Observational Retrospective Multicenter Study.Seminars in thrombosis and hemostasis · 2026Observational
- Seventh Åland Island Meeting on von Willebrand Disease.Haemophilia : the official journal of the World Federation of Hemophilia · 2026Article
- Von Willebrand disease: A century of progress.Research and practice in thrombosis and haemostasis · 2026Review
- A multi-readout photonic sensor for rapid diagnosis of Von Willebrand disease.Npj biosensing · 2026Article
- Integrating Next-Generation Sequencing Into Routine Molecular Diagnosis of Inherited Coagulation Factor Deficiencies: Real-World Data From Spanish Patients.Haemophilia : the official journal of the World Federation of Hemophilia · 2025Article
- von Willebrand Factor (VWF) Inhibitors in Two Brothers with von Willebrand Disease: A Case Report.TH open : companion journal to thrombosis and haemostasis · 2025Article
- Dental Implants and Orthodontic Mini-Screws in a Patient with Undiagnosed Von Willebrand's Disease: A Case Report.Dentistry journal · 2024Article
- Rare inherited coagulation disorders: no longer orphan and neglected.Research and practice in thrombosis and haemostasis · 2024Review
- von Willebrand factor/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand disease.Blood advances · 2024Article
- Acquired von Willebrand Syndrome in a Patient Undergoing Extracorporeal Membrane Oxygenation: A Case Report.Cureus · 2023Article
- Clotting Factor Deficiencies as an Underlying Cause of Abnormal Uterine Bleeding in Women of Reproductive Age: A Literature Review.Life (Basel, Switzerland) · 2023Review
- Thrombotic Pathogenesis and Laboratory Diagnosis in Cancer Patients, An Update.International journal of general medicine · 2023Review
- Article
- Treatment of patients with rare bleeding disorders in the Netherlands: Real-life data from the RBiN study.Journal of thrombosis and haemostasis : JTH · 2022Article
- Platelets' Role in Dentistry: From Oral Pathology to Regenerative Potential.Biomedicines · 2022Review
- Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States.Journal of managed care & specialty pharmacy · 2021Article
- Multiple trauma management in mountain environments - a scoping review : Evidence based guidelines of the International Commission for Mountain Emergency Medicine (ICAR MedCom). Intended for physicians and other advanced life support personnel.Scandinavian journal of trauma, resuscitation and emergency medicine · 2020Article
- Phenotypic and Genotypic Characterization of von Willebrand Factor Gene (Exon 18 and 20) in Saudi Healthy Individuals.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2020Article
- Congenital Bleeding Disorders amid the COVID-19 pandemic: Open questions and recommendations.Acta bio-medica : Atenei Parmensis · 2020Review
- Molecular and clinical profile of type 2 von Willebrand disease in Iran: a thirteen-year experience.International journal of hematology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Along with haemophilia A and B, von Willebrand disease (VWD) and rare bleeding disorders (RBDs) cover all inherited bleeding disorders of coagulation. Bleeding tendency, which can range from extremely severe to mild, is the common symptom. VWD, due to a deficiency and/or abnormality of von Willebrand factor (VWF), represents the most frequent bleeding disorder, mostly inherited as an autosomal dominant trait. The diagnosis may be difficult, based on a bleeding history and different diagnostic assays, which evaluate the pleiotropic functions of VWF. Different treatment options are available for optimal management of bleeding and their prevention, and long-term outcomes are generally good. RBDs are autosomal recessive disorders caused by a deficiency of any other clotting factor, apart from factor XII, and cover roughly 5% of all bleeding disorders. The prevalence of the severe forms can range from 1 case in 500,000 up to 1 in 2-3 million, according to the defect. Diagnosis is based on bleeding history, coagulation screening tests and specific factor assays. A crucial problem in RBDs diagnosis is represented by the non-linear relationship between clinical bleeding severity and residual clotting levels; genetic diagnosis may help in understanding the phenotype. Replacement therapies are differently available for patients with RBDs, allowing the successful treatment of the vast majority of bleeding symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.